Regulations.gov document
Interim Response Letter from FDA CDER to Boehringer Ingelheim USA Corporation
Other · FDA-2020-P-2247 · posted May 28, 2021
Key facts
| Document ID | FDA-2020-P-2247-0020 |
|---|---|
| Title | Interim Response Letter from FDA CDER to Boehringer Ingelheim USA Corporation |
| Document type | Other |
| Subtype | Response(s) |
| Agency | FDA |
| Docket | FDA-2020-P-2247 |
| Posted | May 28, 2021 |
| Comment period opens | May 28, 2021 |
At a glance
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: